GALAFOLD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GALAFOLD (GALAFOLD).
GALAFOLD (migalastat) is a pharmacological chaperone that selectively and reversibly binds to and stabilizes certain mutant forms of α-galactosidase A (α-Gal A). It facilitates proper trafficking of the enzyme to lysosomes, increases lysosomal α-Gal A activity, and reduces accumulation of globotriaosylceramide (GL-3) and its metabolites.
| Metabolism | Migalastat undergoes minimal metabolism. In vitro studies suggest it is not significantly metabolized by CYP450 enzymes. The primary route of elimination is renal excretion as unchanged drug. |
| Excretion | Renal: 77% as unchanged drug; fecal: 0.5%; biliary: negligible. No active metabolites. |
| Half-life | 6-10 hours (terminal half-life); no accumulation at steady state with every-other-day dosing. |
| Protein binding | 67% (primarily to albumin). |
| Volume of Distribution | 0.6-0.8 L/kg (suggests distribution into total body water). |
| Bioavailability | Oral: 51-78% (estimated; absolute bioavailability not determined). |
| Onset of Action | Oral: clinical improvement in neuropathic pain and gastrointestinal symptoms observed within 2-4 weeks of initiation. |
| Duration of Action | Sustained with every-other-day dosing; half-life supports 48-hour dosing interval. |
123 mg orally every other day.
| Dosage form | CAPSULE |
| Renal impairment | eGFR 30-59 mL/min: 123 mg every 3 days; eGFR 15-29 mL/min: 123 mg every 7 days; eGFR <15 mL/min or on dialysis: not recommended. |
| Liver impairment | No adjustment required for mild to moderate impairment (Child-Pugh A or B); not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use with caution due to age-related renal function decline; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GALAFOLD (GALAFOLD).
| Breastfeeding | No human data on presence in breast milk; likely excreted due to low molecular weight. M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential infant exposure. |
| Teratogenic Risk | No adequate human data; animal studies show no evidence of fetal harm at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on limited data. Second and third trimesters: no known specific fetal risks. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["None known"]
| Precautions | ["Elevated alkaline phosphatase levels","Potential for reduced efficacy in patients with severe renal impairment","Monitor renal function and hepatic enzymes","Risk of hypersensitivity reactions","Not recommended in patients with non-amenable GLA variants"] |
Loading safety data…
| No specific monitoring required; standard prenatal care. Monitor renal function and for adverse effects of migalastat (e.g., headache, nasopharyngitis). |
| Fertility Effects | No human data; animal studies show no impairment of fertility at clinically relevant doses. |